"2,600,000 Shares Short - Average Volume Under 300,000"
I expect news of a partnership to surface some time in August. There are too many "big pharma" companies that need to add new drugs to their "pipeline" or replace problematic drugs such as is the situation with GSK with avandia.
Word is getting out on the otential upside here and new buyers are pulling shares out of the float. It's only a matter of time before this gaps to above $5.00 and the runs to the $7.50 range prior to its October 30 PDUFA date.